Accelerated Assessment Dry Spell Over As EMA Says Yes To Pharming’s Leniolisib
MAA Filing Is Planned In October
Leniolisib has become the first product to be granted accelerated assessment status by the European Medicines Agency this year.
You may also be interested in...
UCB’s zilucoplan for treating gMG is among the latest new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.
The Dutch firm has announced its intention to submit US and EU filings for leniolisib and expand development into Japan after the candidate impressed in an ultra-rare disease study.